Abstract
Background: Psoriasis therapeutic goals extend beyond Psoriasis Area and Severity Index (PASI) improvement to reducing psoriasis involvement in special areas and improving patients’ overall well-being. We present the effect of apremilast on the Dermatology Life Quality Index (DLQI), pruritus, and nail, scalp, and palmoplantar involvement in PASI-75 nonresponders.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
